Detail page

Knowledge Web

Person

Rüdiger Hehlmann (1941-)

Internist

Name	Rüdiger Hehlmann
Time	1941- (Date of birth and death)
Place	Deutschland
Gender	männlich
Academic degree	Prof. Dr. med. Ordinarius
Profession	Internist (characteristic profession)
Variant	Rudiger Hehlmann Ruediger Hehlmann R. Hehlmann Rüediger Hehlmann Ruediger Hehlman (falsche Namensform)
Related	Universitätsmedizin Mannheim (III. Medizinische Klinik) (1981-2007) Universität Heidelberg. Medizinische Fakultät Mannheim (1988-) Leukämie (Thema)
Further information	ehemaliger Ordinarius und Professor für Innere Medizin, Hämatologie/Onkologie an der III. Medizinischen Klinik der Medizinischen Fakultät Mannheim der Universität Heidelberg; seit 2008 Emeritus
Record type	Person
GND-Identifier	1037003489
Record ID	1037003489
Involved in show all How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia Survival with chronic myeloid leukaemia after failing milestones Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study Impact of emerging ACA on survival in chronic myeloid leukemia (CML) Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML High-risk additional chromosomal abnormalities at low blast counts herald death by CML Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV Chronic Myeloid Leukemia Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL) Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV Diagnosis and Therapy of Polycythemia Vera Leukocytoclastic Vasculitis and Acute Renal Failure after Influenza Vaccination in an Elderly Patient with Myelodysplastic Syndrome Klinische Forschung im Kompetenznetz „Akute und chronische Leukämien“ Klinische Forschung im „European LeukemiaNet” Chronic myeloid leukemia: a model for oncology BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR) Impact of Chemoradiotherapy-Induced Anemia on Survival in Uniformly Staged Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus Selektive Hemmung von Tyrosinkinasen als neues therapeutisches Prinzip in der Onkologie Therapie der chronischen myeloischen Leukämie 2004 Klinische Forschung im Kompetenznetz „Akute und chronische Leukämien“ Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection—case report and review of the literature Chronische myeloproliferative Erkrankungen : Diagnostik und Therapie Treatment of Relapsed Acute Promyelocytic Leukemia Treatment of a Patient with Advanced Esophageal Cancer with a Combination of Mitomycin C and Capecitabine: Activation of the Thymidine Phosphorylase as Active Principle? Auer rod-like inclusions in multiple myeloma Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy Echokardiographischer Nachweis von Trikuspidalklappen-Vegetationen und rechtskardialen Raumforderungen bei einem Patienten mit akuter myeloischer Leukämie High-Dose 5-Fluorouracil / Folinic Acid in Combination with Three-Weekly Mitomycin C in the Treatment of Advanced Gastric Cancer. A Phase II Study Aktuelle Pharmakotherapie der chronischen myeloischen Leukämie Phase II Study of a Weekly 24-Hour Infusion with 5-Fluorouracil and Simultaneous Sodium – Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer Die Bedeutung der Vernetzung für die klinische Forschung der Zukunft Aktuelle Therapiekonzepte bei akuter Promyelozytenleukämie Predominantly BCR-ABL negative myeloid precursors in interferon-α treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization Chronische myeloische Leukämie : Biologie - Diagnostik - Klinik - Therapie Combination of Bolus 5-Fluorouracil, Folinic Acid and Mitomycin C in Advanced Gastric Cancer: Results of a Phase II Trial Polyzythämia vera : Aktueller Stand der Therapie Interferon α in the treatment of polycythemia vera Untersuchungen zur Nichtinfektiosität doppelsträngiger RNS des Bakteriophagen M 12 in E. coli Sphäroplasten

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Rüdiger Hehlmann (1941-)

How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

Survival with chronic myeloid leukaemia after failing milestones

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Chronic Myeloid Leukemia

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL)

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV

Diagnosis and Therapy of Polycythemia Vera

Leukocytoclastic Vasculitis and Acute Renal Failure after Influenza Vaccination in an Elderly Patient with Myelodysplastic Syndrome

Klinische Forschung im Kompetenznetz „Akute und chronische Leukämien“

Klinische Forschung im „European LeukemiaNet”

Chronic myeloid leukemia: a model for oncology

BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)

Impact of Chemoradiotherapy-Induced Anemia on Survival in Uniformly Staged Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus

Selektive Hemmung von Tyrosinkinasen als neues therapeutisches Prinzip in der Onkologie

Therapie der chronischen myeloischen Leukämie 2004

Klinische Forschung im Kompetenznetz „Akute und chronische Leukämien“

Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient

Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection—case report and review of the literature

Chronische myeloproliferative Erkrankungen : Diagnostik und Therapie

Treatment of Relapsed Acute Promyelocytic Leukemia

Treatment of a Patient with Advanced Esophageal Cancer with a Combination of Mitomycin C and Capecitabine: Activation of the Thymidine Phosphorylase as Active Principle?

Auer rod-like inclusions in multiple myeloma

Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy

Echokardiographischer Nachweis von Trikuspidalklappen-Vegetationen und rechtskardialen Raumforderungen bei einem Patienten mit akuter myeloischer Leukämie

High-Dose 5-Fluorouracil / Folinic Acid in Combination with Three-Weekly Mitomycin C in the Treatment of Advanced Gastric Cancer. A Phase II Study

Aktuelle Pharmakotherapie der chronischen myeloischen Leukämie

Phase II Study of a Weekly 24-Hour Infusion with 5-Fluorouracil and Simultaneous Sodium – Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer

Die Bedeutung der Vernetzung für die klinische Forschung der Zukunft

Aktuelle Therapiekonzepte bei akuter Promyelozytenleukämie

Predominantly BCR-ABL negative myeloid precursors in interferon-α treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization

Chronische myeloische Leukämie : Biologie - Diagnostik - Klinik - Therapie

Combination of Bolus 5-Fluorouracil, Folinic Acid and Mitomycin C in Advanced Gastric Cancer: Results of a Phase II Trial

Polyzythämia vera : Aktueller Stand der Therapie

Interferon α in the treatment of polycythemia vera

Untersuchungen zur Nichtinfektiosität doppelsträngiger RNS des Bakteriophagen M 12 in E. coli Sphäroplasten